Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEFENCE: Dapagliflozin to protect eGFR decline in normoproteinuric non-diabetic CKD
jRCT1071220024Not yet recruiting
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of dapagliflozin in chronic kidney disease (CKD) (2 arms). Primary endpoint: Rate of change in eGFR from 1 to 12 months. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT1071220024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071220024.